Literature DB >> 3144533

Single and multiple dose pharmacokinetics of fleroxacin.

E Weidekamm1, R Portmann, C Partos, D Dell.   

Abstract

Pharmacokinetics of fleroxacin following single and multiple dosing were studied in healthy male volunteers. The characteristics of this new trifluorinated quinolone are the long elimination half-life of approximately 10 h and the high plasma concentrations, which exceed 2 mg/l after an oral dose of 200 mg. These two parameters are a prerequisite for a once daily dosage regimen. A good linear relationship (r = 0.998) was found between administered doses (100-2500 mg) and resulting AUC values. The volume of distribution (Vss) exceeded 1 l/kg and reflects the good tissue penetration. Renal clearance of unbound drug was 104 ml/min and within three days 56% of the dose could be recovered from urine as unchanged drug. Multiple dosing of 800 or 1200 mg fleroxacin once daily over ten days resulted in an accumulation of the drug in the plasma by a factor of 1.4. This value is in agreement with the theoretically predicted accumulation and thus non-linear, time-dependent pharmacokinetics can be excluded. The administered tablets were completely bioavailable (F = 1.0) and a significant first pass metabolism can therefore be excluded.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3144533     DOI: 10.1093/jac/22.supplement_d.145

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  19 in total

1.  Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole.

Authors:  M Boeckh; H Lode; K M Deppermann; S Grineisen; F Shokry; R Held; K Wernicke; P Koeppe; J Wagner; C Krasemann
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

2.  Penetration of fleroxacin and ciprofloxacin into skin blister fluid: a comparative study.

Authors:  T J Lubowski; C Nightingale; K Sweeney; R Quintiliani; J Zhi
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

3.  Successful single-dose prophylaxis of Staphylococcus aureus foreign body infections in guinea pigs by fleroxacin.

Authors:  N Bouchenaki; P E Vaudaux; E Huggler; F A Waldvogel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

4.  Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies.

Authors:  B G Reigner; H A Welker
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

5.  The effect of milk consumption on the pharmacokinetics of fleroxacin and ciprofloxacin in healthy volunteers.

Authors:  J F Hoogkamer; C H Kleinbloesem
Journal:  Drugs       Date:  1995       Impact factor: 9.546

6.  Dose-ranging study of fleroxacin for treatment of uncomplicated Chlamydia trachomatis genital infections.

Authors:  W R Bowie; V Willetts; D W Megran
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

7.  Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin.

Authors:  W R Bowie; V Willetts; P J Jewesson
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

8.  Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients.

Authors:  J Schrenzel; F Cerruti; M Herrmann; T Leemann; E Weidekamm; R Portmann; B Hirschel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

9.  Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis.

Authors:  D E Uehlinger; F Schaedeli; M Kinzig; F Sörgel; F J Frey
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

10.  Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women.

Authors:  M Dan; E Weidekamm; R Sagiv; R Portmann; H Zakut
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.